ReVenG: A phase 2 trial of venetoclax and obinutuzumab in people with relapsed chronic lymphocytic leukaemia

This trial aims to see how effective retreatment with venetoclax and obinutuzumab is in people with chronic lymphocytic leukaemia (CLL) who have previously been treated.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT04895436

Trial aim and background

The aim of this trial is to assess how effective retreatment with venetoclax and obinutuzumab (VenG) is in people who have previously been treated with first line venetoclax in combination with an anti-CD20 antibody such as obinutuzumab. Any side effects and change in the CLL will be assessed. 

Participants in the study will receive intravenous (IV) obinutuzumab and oral venetoclax in 28 day cycles for a total of 6 cycles, followed by either 6 or 18 cycles of venetoclax alone. 

Obinutuzumab is a monoclonal antibody therapy that sticks to a protein called CD20.

Venetoclax is a targeted drug called a BCL-2 inhibitor. BCL-2 is a protein that blocks cell death.

The combination of venetoclax and obinutuzumab is already licensed as a first line treatment for people with CLL.

Who can enter 

Adults with CLL requiring treatment who have previously been treated with venetoclax and an anti-CD20 antibody first line may be eligible for this trial.

Locations 

Recruitment is taking place at the Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.clinicaltrials.gov/study/NCT04895436

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.